Transmission and Immunopathogenesis

  • Raziya BobatEmail author
  • Ashendri Pillay


Vertical mother to child transmission has significantly decreased with the use of antiretroviral therapy (ART) in pregnant women and their babies. The success of prevention of mother to child transmission programmes has resulted in transmission rates decreasing from 3.6% in 2011 to 1.3% in 2017. This has placed SA on track for elimination of HIV via mother to child transmission. Unfortunately, in many developing countries, many women do not seek antenatal care early on in pregnancy and do not receive ART, or, do not adhere to treatment, and do not achieve adequate viral control to prevent transmission of infection to the baby. Infection with the human immunodeficiency virus results in a profound immunosuppression, making the host susceptible to various opportunistic infections and neoplasms. Effects of the virus on the host may be particularly dramatic in children as many of the organ systems are still developing.


HIV-1 Mother to child transmission Risk factors Life cycle Receptors CD4 cells Viral load Virus eradication 


  1. 1.
    World Health Organization (WHO). Mother-to-child transmission of HIV. Available from Accessed on 25 July 2019.
  2. 2.
    Joint United Nations Programme on HIV/AIDS. UNAIDS data 2018. Available from Accessed on 25 July 2019.
  3. 3.
    Goga A, Chirinda W, Ngandu N, Ngoma K, Bhardwaj S, Feucht U, et al. Closing the gaps to eliminate mother-to-child transmission of HIV (MTCT) in South Africa: understanding MTCT case rates, factors that hinder the monitoring and attainment of targets, and potential game changers. S Afr Med J. 2018;108(3a):17.CrossRefGoogle Scholar
  4. 4.
    Weinberg GA, Siberry GK. Pediatric human immunodeficiency virus infection. In: Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 8th ed. Philadelphia: Elsevier; 2014. Scholar
  5. 5.
    Weiss RA. Thirty years on: HIV receptor gymnastics and the prevention of infection. BMC Biol. 2013;11:57.CrossRefGoogle Scholar
  6. 6.
    Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee T, et al. Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med. 2014;161:319–27.CrossRefGoogle Scholar
  7. 7.
    Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med. 1997;336(19):1337–42.CrossRefGoogle Scholar
  8. 8.
    Avila-Rios S, Carlson J, John M, Mallal S, Brumme ZL. Clinical and evolutionary consequences of HIV adaptation to HLA—implications for vaccine and cure. Curr Opin HIV AIDS. May 2019;14(3):194–204.CrossRefGoogle Scholar
  9. 9.
    Rocco J, Mellors JW, Macatangay BJC. Regulatory T cells: the ultimate HIV reservoir? J Virus Erad. 2018;4(4):209–14.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Kumar R, Qureshi H, Deshpande S, Bhattacharya J. Broadly neutralizing antibodies in HIV-1 treatment and prevention. Ther Adv Vaccines Immunother. 2018;6(4):61–8.CrossRefGoogle Scholar
  11. 11.
    Goulder P, Lewin S, Leitman E. Paediatric HIV infection: the potential for cure. Nat Rev Immunol. 2016;16(4):259–71.CrossRefGoogle Scholar
  12. 12.
    Stein J, Storcksdieck Genannt Bonsmann M, Streeck H. Barriers to HIV cure. HLA. 2016;88(4):155–63.CrossRefGoogle Scholar
  13. 13.
    Lauring AS, Andino R. Quasispecies theory and the behaviour of RNA viruses. PLoS Pathog. 2010;6(7):e1001005.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Paediatrics and Child HealthNelson R Mandela School of Medicine, UKZNDurbanSouth Africa

Personalised recommendations